Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensus 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Arix Bioscience's Portfolio Firm Aura Biosciences Prices Nasdaq IPO

10/29/2021 | 02:51am EST


ę MT Newswires 2021
All news about ARIX BIOSCIENCE PLC
2021Sorriso Pharmaceuticals, Inc. announced that it has received $31 million in funding fro..
CI
2021Sorriso Pharmaceuticals, Inc. announced that it expects to receive $31 million in fundi..
CI
2021Arix Bioscience's Investee Raises $34 Million Via Oversubscribed Funding Round
MT
2021Depixus SAS announced that it has received €30.6 million in funding from Lansdowne..
CI
2021Arix Bioscience Unit Autolus Partners With Blackstone To Develop Cancer Therapies
MT
2021Arix Bioscience's Portfolio Firm Aura Biosciences Prices Nasdaq IPO
MT
2021ARIX BIOSCIENCE : Cancels Share Repurchase Program to Focus on Investments
MT
2021Tranche Update on Arix Bioscience plc's Equity Buyback Plan announced on March 15, 2021..
CI
2021Arix Bioscience plc's Equity Buyback announced on March 15, 2021, has expired with 6,42..
CI
2021ARIX BIOSCIENCE : Investee Aura Biosciences Posts Interim Data from Choroidal Melanoma Dru..
MT
More news
Financials
Sales 2021 - - -
Net income 2021 - - -
Net cash 2021 133 M 181 M 181 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 158 M 214 M 214 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 12
Free-Float 71,9%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,27 GBX
Average target price 256,00 GBX
Spread / Average Target 20 057%
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Michael William Bunbury Senior Independent Director
Sector and Competitors